Clonal evolution of < em > Candida albicans, Candida glabrata < /em > and < em > Candida dubliniensis < /em > at oral niche level in health and disease
Conclusion: This is the first study to describe the clonal population structure, persistence and stability of Candida spp. at oral niche level. Future research investigating links between Candida spp. clonality and oral disease should recognise the propensity to micro-variations amongst oral niches in C. albicans and C. dubliniensis identified here.PMID:33796227 | PMC:PMC7971237 | DOI:10.1080/20002297.2021.1894047 (Source: Journal of Oral Microbiology)
Source: Journal of Oral Microbiology - April 2, 2021 Category: Microbiology Authors: Alexander J Moorhouse Rosa Moreno-Lopez Neil A R Gow Karolin Hijazi Source Type: research
SGLT2 inhibitors: A new era for our patients
Nephrol Ther. 2021 Mar 24:S1769-7255(21)00029-8. doi: 10.1016/j.nephro.2020.12.006. Online ahead of print.ABSTRACTSince 2015, 10 randomized clinical trials assessed the cardiovascular safety of SGLT2 inhibitors, and then assessed the potential renal and cardiovascular benefits of these drugs (EMPAREG Outcome, CANVAS, DECLARE, DAPA-HF, CREDENCE, EMPEROR-reduced, VERTIS, DAPA-CKD, SCORED, SOLOIST-WHF) in over 88,000 patients. The results of EMPAREG Outcome showed major renal and cardiovascular protection but they were unexpected. The other trials regarding the effects of dapagliflozin, canagliflozin, empagliflozin and more r...
Source: Nephrologie and Therapeutique - March 28, 2021 Category: Urology & Nephrology Authors: Jean-Michel Halimi Source Type: research
SGLT2 inhibitors: A new era for our patients
Nephrol Ther. 2021 Mar 24:S1769-7255(21)00029-8. doi: 10.1016/j.nephro.2020.12.006. Online ahead of print.ABSTRACTSince 2015, 10 randomized clinical trials assessed the cardiovascular safety of SGLT2 inhibitors, and then assessed the potential renal and cardiovascular benefits of these drugs (EMPAREG Outcome, CANVAS, DECLARE, DAPA-HF, CREDENCE, EMPEROR-reduced, VERTIS, DAPA-CKD, SCORED, SOLOIST-WHF) in over 88,000 patients. The results of EMPAREG Outcome showed major renal and cardiovascular protection but they were unexpected. The other trials regarding the effects of dapagliflozin, canagliflozin, empagliflozin and more r...
Source: Nephrologie and Therapeutique - March 28, 2021 Category: Urology & Nephrology Authors: Jean-Michel Halimi Source Type: research
